Format

Send to

Choose Destination
J Hematol Oncol. 2015 Jul 22;8:88. doi: 10.1186/s13045-015-0180-y.

Role of DNA methylation in renal cell carcinoma.

Author information

1
Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10467, USA. knirajshenoy@gmail.com.
2
Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10467, USA. vnishanth@gmail.com.
3
Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10467, USA. yiyu.zou@einstein.yu.edu.
4
Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10467, USA. nahungaleas@yahoo.com.
5
Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10467, USA. makardhwaj.shrivastava@gmail.com.
6
Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10467, USA. caroline.hu@einstein.yu.edu.
7
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. ksusztak@mail.med.upenn.edu.
8
Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10467, USA. amit.verma@einstein.yu.edu.

Abstract

Alterations in DNA methylation are seen in cancers and have also been examined in clear cell renal cell carcinoma (ccRCC). Numerous tumor suppressor genes have been reported to be partially or completely silenced due to hypermethylation of their promoters in single-locus studies, and the use of hypomethylating agents has been shown to restore the expression of many of these genes in vitro. In particular, members of the Wnt and TGF-beta pathways, pro-apoptotic genes such as APAF-1 and negative cell-cycle regulators such as KILLIN have been shown to be epigenetically silenced in numerous studies in ccRCC. Recently, TCGA analysis of a large cohort of ccRCC samples demonstrated that aberrant hypermethylation correlated with the stage and grade in kidney cancer. Our genome-wide studies also revealed aberrant widespread hypermethylation that affected regulatory regions of the kidney genome in ccRCC. We also observed that aberrant enhancer hypermethylation was predictive of adverse prognosis in ccRCC. Recent discovery of mutations affecting epigenetic regulators reinforces the importance of these changes in the pathophysiology of ccRCC and points to the potential of epigenetic modulators in the treatment of this malignancy.

PMID:
26198328
PMCID:
PMC4511443
DOI:
10.1186/s13045-015-0180-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center